Knocking down PD-L1 and/or IDO1 in GBM cells removes the immunosuppressive effect of IFN-γ-exposed GBM EVs on monocytes, suggesting that these molecules could be considered as possible therapeutic targets to combat GBM EV-mediated immunosuppression (143). The gene discussed is IDO1; the disease is glioblastoma.